Soc. Generale Bonus Zert SNW 27.0.../ DE000SV70WE2 /
| 24/06/2024 08:40:18 | Chg.-0.84 | Bid11:47:40 | Ask11:47:40 | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 105.07EUR | -0.79% | 106.05 Bid Size: 4,000 |
106.17 Ask Size: 4,000 |
SANOFI SA INHABER ... | - EUR | 27/09/2024 | Call |
GlobeNewswire
21/06
Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s ...
GlobeNewswire
21/06
Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusi...
GlobeNewswire
20/06
Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa
GlobeNewswire
18/06
Belharra Therapeutics Announces Strategic Collaboration with Sanofi to Advance Discovery of Novel Sm...
GlobeNewswire
11/06
Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic A...
GlobeNewswire
03/06
Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival ...
GlobeNewswire
31/05
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
GlobeNewswire
31/05
Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
GlobeNewswire
31/05
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type ...
GlobeNewswire
31/05
Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with typ...
GlobeNewswire
27/05
Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible ...
GlobeNewswire
21/05
Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
GlobeNewswire
20/05
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...
GlobeNewswire
20/05
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ...
GlobeNewswire
20/05
Shah Capital Withdraws Proxy Campaign Against Re-Election of Directors at Novavax’s 2024 Annual Meet...
GlobeNewswire
13/05
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 20...
GlobeNewswire
13/05
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Developme...
GlobeNewswire
13/05
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...
